Clinical and pharmacokinetic study of sunitinib and docetaxel in women with advanced breast cancer.
| dc.contributor.author | Bergh, Jonas | |
| dc.contributor.author | Mariani, G | |
| dc.contributor.author | Cardoso, F | |
| dc.contributor.author | Liljegren, A | |
| dc.contributor.author | Awada, A | |
| dc.contributor.author | Viganò, L | |
| dc.contributor.author | Huang, X | |
| dc.contributor.author | Verkh, L | |
| dc.contributor.author | Kern, K | |
| dc.contributor.author | Giorgetti, C | |
| dc.contributor.author | Gianni, L | |
| dc.date.accessioned | 2012-05-09T12:20:21Z | |
| dc.date.available | 2012-05-09T12:20:21Z | |
| dc.date.issued | 2012-02-13 | |
| dc.identifier.citation | Clinical and pharmacokinetic study of sunitinib and docetaxel in women with advanced breast cancer. 2012, 21(4):507-513 Breast | en_GB |
| dc.identifier.issn | 1532-3080 | |
| dc.identifier.pmid | 22336056 | |
| dc.identifier.doi | 10.1016/j.breast.2012.01.012 | |
| dc.identifier.uri | http://hdl.handle.net/10541/222751 | |
| dc.description.abstract | BACKGROUND: This exploratory study examined the pharmacokinetics, safety, and antitumor activity of sunitinib plus docetaxel in patients with HER-2-negative advanced breast cancer. PATIENTS AND METHODS: Patients with HER-2-negative disease who had received prior adjuvant anthracycline-based therapy received docetaxel (75 mg/m(2)) on day 1 of each 3-week cycle followed by sunitinib (37.5 mg/day for 2 weeks on Schedule 2/1) starting on day 2 (day 3 on cycle 2). RESULTS: Twenty-two patients were enrolled. No clinically significant drug-drug interactions were observed. The most common non-hematologic AE (any grade) was fatigue/asthenia. Grade 4 neutropenia occurred in 20/22 patients (91%; n = 7 had neutropenic fever). The safety profile was similar to each agent given individually. 14/19 (73.7%) evaluable patients had a PR and 5/19 (26.3%) had SD. CONCLUSIONS: Sunitinib plus docetaxel on Schedule 2/1 did not result in any clinically significant drug-drug interactions. This combination was manageable and exhibited antitumor activity. | |
| dc.language | ENG | |
| dc.language.iso | en | en |
| dc.rights | Archived with thanks to Breast (Edinburgh, Scotland) | en_GB |
| dc.title | Clinical and pharmacokinetic study of sunitinib and docetaxel in women with advanced breast cancer. | en |
| dc.type | Article | en |
| dc.contributor.department | Karolinska Institutet and University Hospital, Stockholm, Sweden; University of Manchester, Paterson Institute for Cancer Research, Manchester, UK. | en_GB |
| dc.identifier.journal | Breast | en_GB |
| html.description.abstract | BACKGROUND: This exploratory study examined the pharmacokinetics, safety, and antitumor activity of sunitinib plus docetaxel in patients with HER-2-negative advanced breast cancer. PATIENTS AND METHODS: Patients with HER-2-negative disease who had received prior adjuvant anthracycline-based therapy received docetaxel (75 mg/m(2)) on day 1 of each 3-week cycle followed by sunitinib (37.5 mg/day for 2 weeks on Schedule 2/1) starting on day 2 (day 3 on cycle 2). RESULTS: Twenty-two patients were enrolled. No clinically significant drug-drug interactions were observed. The most common non-hematologic AE (any grade) was fatigue/asthenia. Grade 4 neutropenia occurred in 20/22 patients (91%; n = 7 had neutropenic fever). The safety profile was similar to each agent given individually. 14/19 (73.7%) evaluable patients had a PR and 5/19 (26.3%) had SD. CONCLUSIONS: Sunitinib plus docetaxel on Schedule 2/1 did not result in any clinically significant drug-drug interactions. This combination was manageable and exhibited antitumor activity. |